Beam Therapeutics
BEAM
251 hedge funds and large institutions have $2.58B invested in Beam Therapeutics in 2026 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 89 increasing their positions, 61 reducing their positions, and 41 closing their positions.
105% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $7.68M
46% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 61
34% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 41
2% more funds holding
Funds holding: 246 → 251 (+5)
0.97% more ownership
Funds ownership: 105.31% → 106.27% (+0.97%)
13% less capital invested
Capital invested by funds: $2.96B → $2.58B (-$384M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$40.1M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$34.5M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$22.8M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$19M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$27.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$22.4M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$16.2M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$16.2M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$13.7M |
BEAM Hedge Fund Activity: Q1 2026 in Review
251 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2026, worth a combined $2.58B — down 13% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new BEAM positions and 41 closed out — a net gain of 14 holders — while 89 added to existing stakes and 61 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $40.1M. The largest seller was Woodline Partners, exiting entirely with an estimated $27.5M sold.
- 251 institutional investors held Beam Therapeutics (BEAM) as of Q1 2026, up from 246 in Q4 2025.
- Funds reported $2.58B of Beam Therapeutics stock for Q1 2026, down 13% quarter-over-quarter.
- 55 funds opened new Beam Therapeutics positions in Q1 2026 and 41 closed out, a net change of +14 holders.
- The largest Beam Therapeutics buyer in Q1 2026 was ADAR1 Capital Management, an estimated $40.1M added.
- The largest Beam Therapeutics seller in Q1 2026 was Woodline Partners, an estimated $27.5M sold.
Based on aggregated 13F filings for Q1 2026.